← Every applicant
Teva Pharms Inc FDA Approvals
16 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| TOLVAPTANNew drugJul 21, 2026TABLET, ORAL |
| NILOTINIB HYDROCHLORIDENew drugJun 26, 2026CAPSULE, ORAL |
| LO JUNEL FENew drugJun 22, 2026TABLET, ORAL |
| GLYCEROL PHENYLBUTYRATENew drugApr 15, 2026LIQUID, ORAL |
| PRUCALOPRIDE SUCCINATENew drugFeb 5, 2026TABLET, ORAL |
| AMLODIPINE BESYLATENew drugJan 22, 2026TABLET, ORAL |
| ATORVASTATIN CALCIUMNew drugNov 13, 2025TABLET, ORAL |
| DALBAVANCIN HYDROCHLORIDENew drugOct 23, 2025POWDER, INTRAVENOUS |
| MESALAMINENew drugAug 22, 2024TABLET, DELAYED RELEASE, ORAL |
| TIOPRONINNew drugJul 22, 2024TABLET, DELAYED RELEASE, ORAL |
| ALVAIZNew drugNov 29, 2023TABLET, ORAL |
| PAZOPANIB HYDROCHLORIDENew drugOct 19, 2023TABLET, ORAL |
| PACLITAXELNew drugMay 11, 2023POWDER, INTRAVENOUS |
| ALYQNew drugOct 12, 2022TABLET, ORAL |
| THEOPHYLLINENew drugOct 12, 2022TABLET, EXTENDED RELEASE, ORAL |
| CETRORELIX ACETATENew drugAug 12, 2022POWDER, SUBCUTANEOUS |